INTS Intensity Therapeutics, Inc. restarts patient treatment in the randomized, presurgical triple negative breast cancer phase 2 clinical t
INTS Intensity Therapeutics, Inc. restarts patient treatment in the randomized, presurgical triple negative breast cancer phase 2 clinical trial (invincible-4 study)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.